This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
November 26, 2024
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
October 31, 2024
The role of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in the pre- and post-lung transplant population is limited. This specific patient population is considered high risk for general anesthesia and for surgical aortic valve replacement.
October 3, 2024
Aortic stenosis affects more than 9 million people worldwide and is commonly treated with surgical aortic valve replacement (SAVR), which is known for producing excellent long-term outcomes. Recent advancements in transcatheter aortic valve replacement (TAVR) have shown noninferior or improved outcomes compared to SAVR across various risk levels.
August 8, 2024
Treatment of aortic stenosis due to a bicuspid aortic valve (BAV), requires a lifetime strategy due to structural valve degeneration that necessitates redo intervention, such as surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
August 8, 2024
Transcatheter aortic valve replacement (TAVR) has surpassed surgical aortic valve replacements in volume since TAVR is now approved for patients of all surgical risk categories. This article evaluated trainees and program directors to assess current training patterns and comfort levels regarding catheter-based interventions.
July 18, 2024
In this large population-based cohort study, long-term mortality and morbidity were investigated in patients undergoing biological surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) for severe aortic valve stenosis. Individual data from the Austrian Insurance Funds from 2010 through 2020 were analyzed.
July 11, 2024
The number of patients at intermediate and low surgical risk treated by transcatheter aortic valve implantation (TAVI) is rapidly increasing. Current guidelines recommend performing TAVI in heart valve centers with surgical backup.
June 5, 2024
Surgical explantation of transcatheter heart valves (THV) is rapidly increasing, but data on patients with THV-associated infective endocarditis (IE) is lacking. This study assessed the outcomes of patients undergoing THV explant for IE based on data from the international TAVR-EXPLANT Registry.
May 23, 2024
The NOTION-2 trial aimed to compare transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in low-risk patients less than 75 years old, including with both tricuspid and bicuspid aortic stenosis (AS).